Former UFC Middleweight champion Anderson Silva and his UFC 183 opponent Nick Diaz were expected to face the Nevada Athletic Commission at its March 23 meeting regarding their respective failed drug tests in relation to their UFC 183 main event bout.

But as reported by Yahoo Sports, though the NAC meeting will push through, it will do so without both Silva and Diaz.

Both fighters requested continuances for their disciplinary hearings before the commission. NAC executive director Bob Bennett told MMAWeekly that Silva and Diaz were each granted a continuance, which ultimately means both would instead face the commission in its April meeting.

The two fighters sought for more time to prepare for the defenses ahead of the hearing, according to Bleacher Report. They are facing possible fines and suspensions are a result of their failed drug tests.

Silva failed two tests"”the first one was in a Jan. 9 out-of-competition drug test, which revealed traces of two anabolic steroid metabolites for Drostanolone and Androstane.

He passed a subsequent test on Jan. 19, but tested positive again for Drostanolone, along with Oxazepam and Temazepam"”benzodiazepine drugs commonly used to treat anxiety-related insomnia.

Diaz, for his part is in for a disciplinary hearing for testing positive for marijuana metabolites in his fight-night drug test. He has been tested positive for marijuana multiple times before.

In related news, MMAWeekly reports that sources close to Silva informed UFC Tonight that Silva plans to fight again in 2015, depending on the imposed sanctions by the NAC.

This follows a series of contradicting, almost bizarre, reports in the aftermath of Silva's failed drug tests.

"I have not taken any performance enhancing drugs. My stance on drugs is, and will always be, the same. I'm an advocate for a clean sport," Silva said in a released statement last month.

There were also reports that Silva was supposed to admit to using performance-enhancing drugs for therapeutic purposes.

As it stands, a date for the April hearing has yet to be announced.